$BTCY “Lion Stock Alerts” Promoter Rank: 22/25 Biotricity Inc. Newsletter 7:23:02 AM October 7, 2021

on October 7, 2021 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Lion Stock Alerts"

The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":

15%

2 out of 13 campaigns closed down on first day

30%

4 out of 13 campaigns closed up on first day

53%

7 out of 13 campaigns had no net effect

BTCY Promotional Newsletter

The following is a newsletter released by "Lion Stock Alerts" promoting Biotricity Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

LionStockAlerts

Don't Want Anymore Emails

Hello

New Alert Biotricity, Inc. NASDAQ BTCY

We are continuing our coverage of BTCY, a recent alert, and a newly uplisted Nasdaq company that has experienced significant growth over the past year.

Since our last update, BTCY has been consolidating, presenting what could be another opportunity.

In addition, the company has announced several developments recently that could be additional growth catalysts.

Before we discuss the most recent news, here is a brief recap of the company.

BTCY is a medical diagnostic and consumer healthcare technology company that develops comprehensive remote health monitoring solutions for the medical and consumer markets.

The companys FDA-approved Bioflux is a high-precision, single-unit mobile cardiac telemetry MCT device that provides real-time monitoring and transmission of your ambulatory patients ECG information.

As the company further explains

Bioflux enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease by detecting and transmitting probable arrhythmias, along with other diagnostic heart information.

In addition, the companys proprietary remote patient monitoring platform can be leveraged for various industries and plans are underway to pipeline new solutions across a spectrum of health applications, including remote COPD monitoring, fetal monitoring, sleep apnea monitoring, and other chronic conditions.

Since August, the company has announced multiple developments that could position it for increased growth.

As the company recently explained

Since August, the Company has completed a financing to support sales expansion while minimizing dilution and maximizing shareholder value, listed on the Nasdaq exchange, and unveiled its Biokit bundle of wireless cardiac data devices that integrate seamlessly with its Bioflux cardiac-diagnostic offering or operate independently for disease management.

As a reminder, in August, the company announced

Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter

For Q1 Fiscal 2022, management is noting the following highlights

Q1 revenue of $1.76 million represented the 9th consecutive quarter of triple digit YoY growth
Quarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to the corresponding quarter of fiscal 2021, showing continued acceleration over the 227% growth in Q42021, 162% growth in Q32021, and 115% growth in Q22021
Quarterly sequential revenue increased 49% compared to 19% posted in the prior quarter, a significant acceleration bolstered by consistent month-over-month sequential growth
The Company nearly tripled sales with a smaller corresponding increase in Operating Expenses, which rose only 17% to $4.2 million for Q1 FY22 compared to $3.6 million in the prior year

On August 30, the company announced, Biotricity Completes Nasdaq Listing for total gross proceeds to the Company of approximately $15 million.

In September, the company announced

Biotricity Unveils Biokit with 3 Personal Medical Devices to Expand into Cardiac Disease Management

REDWOOD CITY, CA ACCESSWIRE September 14, 2021 Biotricity Inc. NASDAQBTCY, a medical diagnostic and consumer healthcare technology company, today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff. All three devices are FDA cleared, wireless capable and integrate into the Biotricity ecosystem, a platform for interconnectivity. This is the next step in the evolution of the Bioflux solution, where other available tools are fully integrated to create a complete solution for remote cardiac monitoring.

In addition, over the past month, the company has participated at multiple conferences

Biotricity to Discuss Sales Expansion, Recent Financing, and Wearable Medical Device Portfolio Expansion at H.C. Wainwright Conference
Biotricity to Discuss Expansion of Remote Monitoring Medical Device Products at Oppenheimer Fall Healthcare Life Sciences MedTech Summit
Biotricity to Discuss its 2022 Strategic Outlook and Product Pipeline, at Benzinga Healthcare Small Cap Conference

Moreover, yesterday, the company announced

Remote Medical Diagnostic Company, Biotricity, to Ring the Nasdaq Stock Market Opening Bell on Thursday, October 7th

As more investors discover this company, they could notice what we believe to be an overlooked opportunity.

Make sure to do your own due diligence.

Sources , , , , , , , , , , , , ,

Happy Trading

LionStockAlerts

Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.

--------------------------

DISCLAIMER

You should read and understand this disclaimer in its entirety before joining the website or emailblog list of LionStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 10621 for the distribution of this advertisement about BTCY dated 10721. Previously, owners and operators of the Publisher have been compensated twenty two thousand five hundred dollars by bank wire transfer on 83021 for the distribution of a prior advertisement about BTCY. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this reportrelease because you subscribed to receive it at our website or through a third-party site. All our newsletters include an unsubscribe link, and you can remove yourself at any time from our newsletters by clicking on that unsubscribe link. You can also contact us at infoLionStockAlerts.com to change your information at any time. By your subscription to our profiles, the viewing of this profile andor use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link

www.LionStockAlerts.comDisclaimer and www.LionStockAlerts.comPrivacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.

6020 Bent Pine Drive
Orlando FL 32828
USA